Meningitis: A collection of articles and pages from the web:
A handy one stop reference

Links to a 1 sheet (double sided) Printable Brochure on Meningitis
WVIN tri-fold Brochure 11" x 8.5" (PDF 377K)
Brochure in HTML format



http://users.adelphia.net/~cdc/Vaccines.htm

The Vaccines

Package Inserts and information for each vaccine.


http://users.adelphia.net/~cdc/Vaccines.htm#Meningococcal

Meningococcal

Menomune®-A/C/Y/W-135 Meningococcal Polysaccharide Vaccine Groups A, C, Y and W-135 Combined-Manufactured by: Aventis Pasteur Inc. Swiftwater PA 18370 USA

AC Vax-Meningococcal Polysaccharide vaccine (groups A and C polysaccharides)- Marketing Authorisation Holder SmithKline Beecham PLC 980 Great West Road Brentford Middlesex TW8 9GS Trading as: GlaxoSmithKline UK Stockley Park West Uxbridge Middlesex UB11 1BT

ACWY Vax-Meningococcal Polysaccharide vaccine (groups A, C, W135 and Y polysaccharides)-Marketing Authorisation Holder SmithKline Beecham PLC 980 Great West Road Brentford Middlesex TW8 9GS Trading as: GlaxoSmithKline UK Stockley Park West Uxbridge Middlesex UB11 1BT




http://www.fda.gov/cber/vaccine/thimerosal.htm#t3

Last Updated: 10/6/2003


Thimerosal Content in Currently Manufactured U.S. Licensed Vaccines

Vaccine

Trade Name

Manufacturer

Thimerosal Concentration1

Mercury



Meningococcal

Menomune A, C, AC and A/C/Y/W-135

Aventis Pasteur, Inc.

0.01% (multidose)
0 (single dose)

25 µg/0.5 dose
0


Thimerosal is approximately 50% mercury (Hg) by weight. A 0.01% solution (1 part per 10,000) of thimerosal contains 50 µg of Hg per 1 ml dose or 25 µg of Hg per 0.5 ml dose.




http://www.whale.to/a/thimerosal2002.html#2

Thimerosal Content in Some US Licensed Vaccines

updated 02-21-2002

http://www.vaccinesafety.edu/thi-table.htm

When I went to the vaccinesafety.edu site, I found this, which was updated in January, 2004.

http://www.vaccinesafety.edu/thi-table.htm#* [excerpt below 2003, updated 01/13/2004]



Vaccine  Brand Name Manufacturer  Thimerosal  Mercury    Date Approved  pg in 2003

  (click on name Concentration ug/0.5 ml or Changed PDR

for package insert)  


Meningo- MENOMUNE   Aventis * *  807

Coccal -A/C /Y/W-135 Pasteur



*This product should be considered equivalent to thimerosal-free products. This vaccine may contain trace amounts (<0.3 cmg) of mercury left after post-production thimerosal removal; these amounts have no biological effect. JAMA 1999;282(18) and JAMA 2000;283(16).



A concentration of 1:10,000 is equivalent to a 0.01% concentration. Thimerosal is approximately 50% Hg by weight.   A 1:10,000 concentration contains 25 micrograms of Hg per 0.5 mL.


   
http://www.us.aventispasteur.com/PRODUCT/PDFFILES/Menomune.pdf is the link to the package insert for Menomune A/C/Y/ W-135




http://www.vaccinationnews.com/DailyNews/June2001/VaccineIngredients.htm


Menomune
Meningococcal Polysaccharide Vaccine
Connaught Laboratories
1-800-822-2463
produced using thimerosal, lactose
medium: freeze dried polysaccharride antigens from Neisseria Meningitidis




Below the following excerpt from the package insert (for the Aventis Pasteur Menomune Meningococcal vaccine), is Centers for Disease Control (CDC) information about the Meningococcal Vaccine. Its statements are not in agreement with the statements in the package insert found at http://www.us.aventispasteur.com/PRODUCT/PDFFILES/Menomune.pdf . [February 2001 package insert -- The web page that was updated January, 2004, said to click on the vaccine name in order to see the package insert. The insert that you get when you click on Menomune is this one from February, 2001.]


The package insert says:


Menomune – A/C/Y/W-135 has not been evaluated in animals for its carcinogenic, mutagenic potentials or impairment of fertility.

Pregnancy

Reproductive Studies – Pregnancy Category C

Animal reproduction studies have not been conducted with Meningococcal Polysaccharide Vaccine, Groups A,C, Y and W-135. It is also not known whether Meningococcal Polysaccharide Vaccine, Groups A,C, Y and W-135 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Meningococcal Polysaccharide Vaccine, Groups A,C, Y and W-135 should be given to a pregnant woman only if clearly needed. Although there is limited data, studies to date have found no evidence of teratogenicity [tendency to cause fetal malformation] of the polysaccharide quadrivalent meningococcal vaccine when given to pregnant women. [25]

[25] Letson, GW, et al. Meningococcal vaccine in pregnancy: an assessment of infant risk. Pediatr Infect Dis J 17(3), 261-263, 1998


Contraindications

Immunization should be deferred during the course of any acute illness.

It is a contraindication to administer Menoumune – A/C/Y/W-135 to individuals known to be sensitive to thimerosal or any other component of the vaccine. For individuals sensitive to thimerosal, administer the one dose package size and reconstitute with the 0.78 ml vial of diluent that contains no preservative.






http://www.cdc.gov/nip/publications/VIS/vis-mening.txt


Vaccine Information Statement


MENINGOCOCCAL VACCINE


WHAT Y0U NEED TO KN0W


1. What is meningococcal disease?


Meningococcal disease is a serious illness, caused by a bacteria. It is the leading cause of bacterial meningitis in children 2-18 years old in the United States. Meningitis is an infection of the brain and spinal cord coverings. Meningococcal disease can also cause blood infections.


About 2,600 people get meningococcal disease each year in the U.S. 10-15% of these people die, in spite of treatment with antibiotics. Of those who live, another 10% lose their arms or legs, become deaf, have problems with their nervous systems, become mentally retarded,

or suffer seizures or strokes.


Anyone can get meningococcal disease. But it is most common in infants less than one year of age, and in people with certain medical conditions. College freshmen, particularly those who live in dormitories, have a slightly increased risk of getting meningococcal disease.


Meningococcal vaccine can prevent 4 types of meningococcal disease. These include 2 of the 3 types most common in the United States and a type which is the main cause of epidemics in Africa. Meningococcal vaccine cannot prevent all types of the disease. But it does help to protect many people who might become sick if they don't get the vaccine.


Drugs such as penicillin can be used to treat meningococcal infection. Still, about 1 out of every ten people who get the disease dies from it, and many others are affected for life. This is why it is important that people with the highest risk for meningococcal disease get the vaccine.


2. Who should get meningococcal vaccine and when?


Meningococcal vaccine is not routinely recommended for most people. People who should get the vaccine include:


U.S. Military recruits


People who might be affected during an outbreak of certain types of meningococcal disease.


Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as West Africa.


Anyone who has a damaged spleen, or whose spleen has been removed.


Anyone who has terminal complement component deficiency (an immune system disorder).



The vaccine should also be considered for:


Some laboratory workers who are routinely exposed to the meningococcal bacteria.


The vaccine may also be given to college students who choose to be vaccinated. College freshmen, especially those who live in dormitories, and their parents should discuss the risks and benefits of vaccination with their health care providers.


Meningococcal vaccine is usually not recommended for children under two years of age. But under special circumstances it may be given to infants as young as 3 months (the vaccine does not work as well in very young children). Ask your health care provider for details.


How many doses?


-- For people 2 years of age and over: 1 dose (Sometimes an additional dose is recommended

for people who continue to be at high risk. Ask your provider.)


-- For children 3 months to 2 years of age who need the vaccine: 2 doses, 3 months apart



3. Some people should not get meningococcal vaccine or should wait


People should not get meningococcal vaccine if they have ever had a serious allergic reaction to a previous dose of the vaccine.


People who are mildly ill at the time the shot is scheduled can still get meningococcal vaccine. People with moderate or severe illnesses should usually wait until they recover. Your provider can advise you.


Meningococcal vaccine may be given to pregnant women.


4. What are the risks from meningococcal vaccine?


A vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of the meningococcal vaccine causing serious harm, or death, is extremely small.


Getting meningococcal vaccine is much safer than getting the disease.


Mild problems


Some people who get meningococcal vaccine have mild side effects, such as redness or pain where the shot was given. These symptoms usually last for 1 -2 days.


A small percentage of people who receive the vaccine develop a fever.



5. What if there is a serious reaction?


What should I look for?


Look for any unusual condition, such as a severe allergic reaction, high fever, or unusual behavior. If a serious allergic reaction occurred, it would happen within a few minutes to a few hours after the shot. Signs of a serious allergic reaction can include difficulty breathing,

weakness, hoarseness or wheezing, a fast heart beat, hives, dizziness, paleness, or swelling of the throat.


What should I do?


Call a doctor, or get the person to a doctor right away.


Tell your doctor what happened, the date and time it happened, and when the vaccination was given.

Ask your health care provider to file a Vaccine Adverse Events Reporting System (VAERS) form. Or call VAERS yourself at 1-800-822-7967 or visit their website at http://www.vaers.org.


6. How can I learn more?


Ask your doctor or nurse. They can give you the vaccine package insert or suggest other sources of information.


Call your local or state health department's immunization program.


Contact the Centers for Disease Control and Prevention (CDC):

- Call 1-800-232-2522 (English)

- Call 1-800-232-0233 (Espanol)

- Visit the National Immunization Program' s website at www.cdc.gov/nip

- Visit the National Center for Infectious Disease's meningococcal disease website at

www.cdc.gov/ncidod/dbmd/diseaseinfo/meningococcal_g.htm

- Visit CDC's Travelers Health website at www.cdc.gov/travel



U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Disease Control and Prevention

National Immunization Program


Vaccine Information Statement

Meningococcal

7/28/2003



http://www.vaccinationnews.com/Scandals/2004/Jan_7/Scandal70.htm

Scandals: Another Unnecessary Vaccine?  Here Comes the Hype for a New Meningitis Vaccine   

Scandals - 1/07/04

Another Unnecessary Vaccine?  Here Comes the Hype for a New Meningitis Vaccine

by Sandy Mintz

The headlines are arresting, the hope almost palpable:  Vaccine 'could beat meningitis';  Scientists: Meningitis Vaccine Breakthrough; Meningitis experts pin hopes on new vaccine; Research Raises Hope for New Meningitis Vaccine.

But what is this "meningitis" and can a vaccine really protect us from it?  According to the CDC, "Meningitis is an infection of the fluid of a person's spinal cord and the fluid that surrounds the brain. People sometimes refer to it as spinal meningitis. Meningitis is usually caused by a viral or bacterial infection. Knowing whether meningitis is caused by a virus or bacterium is important because the severity of illness and the treatment differ. Viral meningitis is generally less severe and resolves without specific treatment, while bacterial meningitis can be quite severe and may result in brain damage, hearing loss, or learning disability. For bacterial meningitis, it is also important to know which type of bacteria is causing the meningitis because antibiotics can prevent some types from spreading and infecting other people. Before the 1990s, Haemophilus influenzae type b (Hib) was the leading cause of bacterial meningitis, but new vaccines being given to all children as part of their routine immunizations have reduced the occurrence of invasive disease due to H. influenzae. Today, Streptococcus pneumoniae and Neisseria meningitidis are the leading causes of bacterial meningitis."

Sounds pretty scary, and it certainly can be.  But as with anything involving for-profit drugs and other biological products, the hype must be separated from the hope. 

First, it must be determined what the incidence of the disease has been, both before and after introduction of vaccination, in order to ascertain if there has been a benefit from vaccination, i.e., it has caused a decline in disease incidence.  As part of determining whether or not the vaccine is responsible for any declines, incidence of meningococcal disease among the vaccinated must then also be compared to those receiving no meningococcal vaccine, particularly those who have never been vaccinated, period.  Finally, the cost (as in negative consequences) of vaccinating must be honestly and fairly compared to the costs of not vaccinating. 

Sadly, even the incidence of meningitis is not all that well-established. Currently (as of year-end 2002), only Haemophilus influenzae and certain forms of Streptococcus pneumonia are separately notifiable, with all other meningococcal disease being reported together.

What is known is fairly reassuring, though:  bacterial meningitis, although dramatic and frightening, is thought to be quite rare and not highly contagious, only affecting "about 2,400-3,000 people" in the United States each year.  (Although the data are a bit confusing.  For instance, although in 2000, according to the CDC, there were fewer than 2400 cases reported in the combined category "meningococcal disease", it is unclear whether or not that figure includes both bacterial and viral meningitis.  On the other hand, it does not include the over 4500 cases of Streptococcus pneumoniae reported that year as well.  Still, the numbers are relatively small.)

Being armed with historical morbidity and mortality data is of little value without additional information, however.  Unfortunately that information is also not available.  Little to nothing is known about whether or not vaccination is necessarily causally related to either a decline in deaths or a decline in incidence, since no long-term studies comparing the vaccinated to the never vaccinated have ever been conducted.  Nor is much known about the possible negative consequences of vaccinating, if there are any.  (Although it is true that there have been 644 adverse meningitis vaccine-associated reactions reported to VAERS so far, indefensibly, it is unknown if they represent 644, 6,440 or even 64,400 cases!  Nor do we know if and when the vaccine actually caused the reported events.)

Regardless, it is becoming increasing clear that the consequences of vaccinating against meningitis may well be regrettable in the long run.  The bacteria targeted by vaccination, rather than remaining content to retreat into the background like a dutiful troop of shrinking violets, seem determined to survive and thrive - and one way they appear to be doing so is by changing serotype and serotype prevalence.  Thus vaccination, rather than removing or diminishing the threat of disease, may instead create an endless ostensible need for additional vaccines by causing pathogens to re-emerge in different forms.

At some point might it not be prudent to question "Public Health's" debatable vaccination policy, the strategy it has adopted in what increasingly appears to be a misguided "war against disease"?  At some point wouldn't it make sense to take a stab at fashioning some other disease prevention/disease survival plan?

Perhaps now would be a good time to start - by not buying into the hysteria about a rare disease and by questioning the drug company solution to preventing it.  For while it is eminently clear that the vaccine manufacturers and those with financial ties to them benefit from the ever-increasing putative need for vaccines,  the more important question is, does anyone else?

(To read a related column on this topic, go to Scandals: Changing Disease Epidemiology Via Vaccines - Are We "Robbing Peter To Pay Paul"?.)

Sandy Mintz               

"Eternal vigilance is the price of liberty." - Wendell Phillips (1811-1884), paraphrasing John Philpot Curran (1808)

Sandy Mintz is the publisher of the website "Vaccination News", and writer of  the columns "Scandals" and "Out of Control".  To join her political action egroup or learn more about it, please send an email to sandym@touchngo.com, indicating the purpose  of your email in the subject line.

Past Scandals and Out of Control.

              

                                                                            Vaccination News    

Breaking News Archives - each day's breaking news from December 1, 2003 (check here for breaking news you might have missed and breaking news that didn't ever hit the "front page")

More News - all the news most recently posted on this website

All the News - a running tab of everything posted on this website since October 29, 2003

Top Stories Archives - daily breaking and other important news stories

Daily News Archives - all the news posted on this website each day (from April 2001)

Hot Topics - selected stories, by category

Return to Vaccination News Home Page (for best results, right click to "open in new window")

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

click here to download Adobe Reader    click here for Picks of the Week    click here for the old "Recommended List"



©Copyright 2003 by Sandy Mintz. All Rights Reserved. This content may be copied in full ONLY with copyright, contact, creation, authorship, and information intact (including all links), without specific permission, and ONLY when used in a not-for-profit format. If any other use is desired, permission in writing from Sandy Mintz is required.

Return to Vaccination News Home Page (for best results, right click to "open in new window")

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.



 

Vaccination Information Service

Whom do you trust, nature or man?

HOME  ARTICLES  LINKS  CHALLENGE FROM US  EMAIL 

BROCHURES  VIDEO/DVD  OTHER BOOKS/VIDEOS  ORDER

NEW! General information brochures - educate your local community!



Vaccination Information Service

http://www.vaccination.inoz.com/meningococcal.html
 

Meningococcal C vaccination
 
Ignoring the Nuremberg Code - a mass medical experiment without informed consent.

 

Bronwyn Hancock November 2003

 

Apart from what is common to all vaccines – the noxious nature of the ingredients, the sensitisation (= opposite of immunisation) effect of injecting these and indeed any other foreign substances into the body, and the other information on the general information brochures and articles on this site about vaccination, the following points are the most important that relate to this particular vaccine. Most of this information, despite being well established, is not passed to parents, contrary to the legal duty of care obligations (Rogers vs Whitaker 1992 175 CLR 479) of all those in Australia responsible for the vaccine’s administration:

 

Vaccine's protective effectiveness undemonstrated, and the violation of your rights

 

The vaccine is admitted by the manufacturer not to have been tested for protective effectiveness. The government's explanation of this, that you will get when you ask, is that it is too soon and it is claimed that you need at least 95% coverage to get to the theoretical “herd immunity” level from which you can determine whether or not it works. Yet only those under 19 years of age are being targeted for the vaccine.

 

Most importantly, it is a violation of the Nuremberg Code and the World Medical Association Declaration of Helsinki to perform an experiment on people without their (or their parent/guardian’s) informed consent, which includes not only its experimental nature but also information about adverse effects already observed and listed below, which information is not provided either.

 

Vaccine contents

 

The ingredients in the meningococcal vaccines can include, but are not limited to: thiomersal (mercury compound), meningococcal oligosaccharide, diphtheria protein or tetanus toxoid, aluminium hydroxide, phenol, mannitol, sodium phosphate monohydrate, sodium phosphate dibasic heptahydrate and sodium chloride. The vaccines are contraindicated (not recommended) for any person who may be hypersensitive to any component.

 

The vaccine's purpose - the meningococcus bacteria, the risk and what causes infections

 

The meningococcus bacteria exists in 5-20% of the population at any given time, and yet meningococcal infections, particularly the "C" strain that is being targeted by this vaccine, are very rare. The risk of infection by the "C" strain is 1 in 135,000. Bacteria of many kinds inhabit the body prolifically, and indeed many, including perhaps meningococcus itself, have an important role in maintaining our survival. Clearly then, it is not simply the presence of the bacteria that causes meningitis.

 

So what does cause meningococcal meningitis? Bacteria have been described as “pleomorphic”, meaning “many forms”. This is because they are very adaptive to their environment – they change into different forms ranging from protective to pathogenic, depending on the environment that they are inhabiting in the body. An unhealthy environment in the body provokes bacteria to change into more virulent forms.

 

Vaccines of all descriptions contain highly noxious substances and have been well documented to provoke severe invasive bacterial infections, including meningococcal meningitis. Indeed there is even a term, "window of opportunity", that refers to the 90 day period after vaccination in which there is an acknowledged increase in susceptibility to such infections.

 

It is also important to note that even once a person contracts meningitis their fate is not sealed, because bacterial meningitis has been treated effectively, bringing people back from death's door, using such support to the immune system as significant doses of intravenous Vitamin C. Please be aware, though, that a hospital will only administer alternative treatments when specifically instructed to by you - otherwise regimens that weaken the immune system are employed, particularly antibiotics, and the consequences can be fatal.

 

Vaccine adverse effects

 

- “increased meningococcal carriage rates”, i.e. the opposite of its purpose

 

And sure enough (following on from the last point) one of the adverse effects listed on the product insert itself is “increased meningococcal carriage rates”. Interestingly a mother who rang recently spoke of a child hospitalised with meningococcal meningitis within a week or two of having the vaccine. The hospital to date will not reveal what strain of meningococcus is involved.

 

Adverse effects also include provocation of meningococcal B meningitis (The Lancet Vol 359 May 25, 2002). The B strain is involved in 50-55% of cases (twice as many as the C strain) and this meningitis seems to be more deadly amongst the younger age group, accounting for at least 2/3 of all deaths in this age group. A recent Australian documentary (Catalyst, ABC TV) stated that the mass vaccination campaign for "C" strain conducted in the UK in 1999 was an experiment to "see what would happen" to the incidence of the "B" strain, which increased by 25%.

 

- other adverse effects

 

Other than the above, other adverse effects listed on product inserts for this vaccine include local reactions, fever, fatigue, restlessness, URTI disease, malaise, headache, myalgia, arthralgia, irritability, light headedness, anorexia, gastrointestinal upset, lymphadenopathy and neurological reactions.

 

Many other effects have also been observed, e.g. haemorrhoids, varicose veins, dizziness, leukopenia, low blood pressure, low insulin levels, low iron levels, severe memory problems, disturbed muscle co-ordination, periarthropathy, lateral epicondylopathy, tendon destruction, cramps and night sweats. This last group of effects and those in the previous list all occurred in one woman, who had had three doses of this vaccine, and became progressively worse after each dose. (She was a student at a university in the UK where 3 doses are given, and she was told she must have the vaccine, all 3 doses, to do her studies. Why do they only give one dose in Australia? Well, just wait and see how long it takes for the public to be told that only one dose is ineffective - so you *really* "have to" have three.)

 

16,527 adverse effects were reported from the vaccine in 10 months of use in the UK, which is more than the number reported in more than 37 years of use of the DPT vaccine, which itself is said to be one of the most reactive vaccines. When it is known that less than 10% of reactions are reported, with some estimates as low as 1%, the total number of adverse effects is very much greater and this is a real concern.

 


 
 

 


Copyright (C) 1998-9 Taycare Pty Ltd

 

Web Designed and Hosted by Breakfast Bytes Pty Limited
Domain Name Sponsored by MyName - My Own Domain Name - FREE!

 

http://www.avn.org.au/Merchant2/merchant.mv?Screen=PROD&Store_Code=AVNI&Product_Code=MIP


Meningitis Information Pack 
  
Quantity in Basket: none
Code: MIP
Price: $16.00

 

Shipping Weight: 0.00 kilos
 
Quantity:   
  
The government and media paint a picture of meningitis as the new 'plague' waiting around the corner to strike down unsuspecting children and young adults.
Find out who really is and who is not at risk of contracting meningitis and why.

 

This pack will answer questions such as:

 

Why if all of us have the bacteria capable of causing meningitis in our bodies, do only some of us actually contract the disease?

 

What are the ingredients of the vaccines (Pneumococcal, Meningococcal and Hib) and what are the side effects associated with these vaccines?

 

How effective are the vaccines? What sorts of studies were carried out prior to their licensing?

 

Since the introduction of these vaccines, has the rate of meningitis gone up or down?

 

These questions and more will be answered by this informative package of information for both mainstream and popular sources.

 

Price includes shipping and GST within Australia - please email sales@avn.org.au for a quote on shipping overseas.

 

To convert this amount to your country's currency, click here http://www.xe.com/pca/

 


HOME  |  VACCINATIONS INFO  |  REPORT A REACTION  |   JOIN THE AVN
 MEMBERS SECTION | CHILDREN'S GALLERY  |  TAKE ACTION  |  PRESS RELEASES
PROFESSIONAL MEMBERS  |  CONTACT THE AVN | GUESTBOOK  |  LINKS

 

AVN SHOP - Books, Packs, Videos, Merchandise

 

Copyright © 2001, AVN Inc. All Rights Reserved. Information is based on the
best available resources. 
Opinions reflect judgment at the time and are subject to change.
Privacy

 

Web Design and Search Engine Optimisation by 1st Place Design
 
Home Page Subscriber Competitions



http://www.musa.org/symptoms.htm

Meningitis Foundation of America

Meningitis Symptoms


Wyoming Vaccine Information Network


Susan Pearce

WVIN address: P.O. Box 615
Buffalo, Wyoming 82834
home (307) 655-2574      
spearce@vcn.com

Jacque Jones
WVIN
P.O. Box 615
Buffalo, Wyoming 82834
home: (307) 684-2969      
jacquefj@msn.com

About Susan:

Susan Oltion Pearce is the co-founder of Wyoming Vaccine Information Network. She spent nearly all of her life in Wyoming, and spent her school years in Sheridan and Natrona Counties. She graduated from the University of Wyoming in 1971 with a B.A. degree in elementary education and taught in Campbell and Big Horn Counties. She is married to a petroleum engineer, Leonard Donald Pearce, and they are the parents of four sons. Susan was a home school mother and an Emergency Medical Technician. Don and Susan are active in the Republican Party.

Susan Pearce and Jacque Jones started the vaccine information/support group in April of 2001. They have monthly meetings, open to the public, in Sheridan and Buffalo, Wyoming, eight months of the year. Jacque and Susan would like to travel to other parts of the state in order to demonstrate to other interested people how to set up meetings of their own. They are set up in a series of four, each covering a different topic concerning vaccination and building a healthy immune system. Jacque and Susan are available to talk to service organizations and other support groups. They occasionally are guests on radio programs.



DISCLAIMER FOR WYOMING VACCINE INFORMATION NETWORK
-- SUSAN PEARCE AND JACQUE JONES

Any information contained herein is for educational purposes only. It is not to be construed as legal or medical advice. Wyoming Vaccine Information Network does not necessarily agree with all the statements made in this material. The decision to vaccinate is one that must be made by you in consultation with a trusted health care provider of your choice.

Please be aware that all information that you read needs to be read carefully, keeping in mind that some of it may not be backed by facts. It is necessary to check on the sources to be certain that a statement is true.

This applies to both sides of the vaccination debate.



Links to a 1 sheet (double sided) Printable Brochure on Meningitis
WVIN tri-fold Brochure 11" x 8.5" (PDF 377K)
Brochure in HTML format